Menu
Search
|

Menu

Close
X

Gemphire Therapeutics Inc GEMP.OQ (NASDAQ Stock Exchange Global Market)

6.60 USD
-0.02 (-0.30%)
As of Feb 17
chart
Previous Close 6.62
Open 6.64
Volume 22,674
3m Avg Volume 21,867
Today’s High 6.72
Today’s Low 6.42
52 Week High 21.59
52 Week Low 6.10
Shares Outstanding (mil) 10.63
Market Capitalization (mil) 110.31
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.594
FY16
-1.304
FY15
-1.746
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
6.21
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-580.12
14.43
Return on Equity (TTM)
vs sector
-3,285.30
16.13

EXECUTIVE LEADERSHIP

Charles Bisgaier
Chairman of the Board, Chief Scientific Officer, Since 2014
Salary: $300,000.00
Bonus: $54,000.00
Steven Gullans
Interim President, Interim Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Mina Sooch
President, Chief Executive Officer, Director, Since 2014
Salary: $380,645.00
Bonus: $102,500.00
Jeffrey Mathiesen
Chief Financial Officer, Since 2015
Salary: $280,645.00
Bonus: $15,000.00
Lee Golden
Chief Medical Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

17199 N Laurel Park Dr Ste 401
LIVONIA   MI   48152-7905

Phone: +1248.9806538

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.

SPONSORED STORIES